Acute spinal cord injury, part II: Contemporary pharmacotherapy

Randall J. Dumont, Subodh Verma, David O. Okonkwo, R. John Hurlbert, Paul T. Boulos, Dilantha B. Ellegala, Aaron S. Dumont

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Spinal cord injury (SCI) remains a common and devastating problem of modern society. Through an understanding of underlying pathophysiologic mechanisms involved in the evolution of SCI, treatments aimed at ameliorating neural damage may be developed. The possible pharmacologic treatments for acute spinal cord injury are herein reviewed. Myriad treatment modalities, including corticosteroids, 21-amino-steroids, opioid receptor antagonists, gangliosides, thyrotropin-releasing hormone (TRH) and TRH analogs, antioxidants and free radical scavengers, calcium channel blockers, magnesium replacement therapy, sodium channel blockers, N-methyl-D-aspartate receptor antagonists, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid-kainate receptor antagonists, modulators of arachadonic acid metabolism, neurotrophic growth factors, serotonin antagonists, antibodies against inhibitors of axonal regeneration, potassium channel blockers (4-aminopyridine), paclitaxel, clenbuterol, progesterone, gabexate mesylate, activated protein C, caspase inhibitors, tacrolimus, antibodies against adhesion molecules, and other immunomodulatory therapy have been studied to date. Although most of these agents have shown promise, only one agent, methylprednisolone, has been shown to provide benefit in large clinical trials. Given these data, many individuals consider methylprednisolone to be the standard of care for the treatment of acute SCI. However, this has not been established definitively, and questions pertaining to methodology have emerged regarding the National Acute Spinal Cord Injury Study trials that provided these conclusions. Additionally, the clinical significance (in contrast to statistical significance) of recovery after methylprednisolone treatment is unclear and must be considered in light of the potential adverse effects of such treatment. This first decade of the new millennium, now touted as the Decade of the Spine, will hopefully witness the emergence of universal and efficacious pharmacologic therapy and ultimately a cure for SCI.

Original languageEnglish (US)
Pages (from-to)265-279
Number of pages15
JournalClinical Neuropharmacology
Volume24
Issue number5
DOIs
StatePublished - Oct 9 2001
Externally publishedYes

Fingerprint

Spinal Cord Injuries
Drug Therapy
Methylprednisolone
Thyrotropin-Releasing Hormone
Therapeutics
Gabexate
Potassium Channel Blockers
Sodium Channel Blockers
Clenbuterol
Kainic Acid Receptors
4-Aminopyridine
Serotonin Antagonists
Free Radical Scavengers
Caspase Inhibitors
Narcotic Antagonists
Immunomodulation
Antibodies
Protein C Inhibitor
Gangliosides
Steroid Receptors

Keywords

  • Drug therapy
  • NASCIS clinical trials
  • Pharmacotherapy
  • Spinal cord injury

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Dumont, R. J., Verma, S., Okonkwo, D. O., Hurlbert, R. J., Boulos, P. T., Ellegala, D. B., & Dumont, A. S. (2001). Acute spinal cord injury, part II: Contemporary pharmacotherapy. Clinical Neuropharmacology, 24(5), 265-279. https://doi.org/10.1097/00002826-200109000-00003

Acute spinal cord injury, part II : Contemporary pharmacotherapy. / Dumont, Randall J.; Verma, Subodh; Okonkwo, David O.; Hurlbert, R. John; Boulos, Paul T.; Ellegala, Dilantha B.; Dumont, Aaron S.

In: Clinical Neuropharmacology, Vol. 24, No. 5, 09.10.2001, p. 265-279.

Research output: Contribution to journalArticle

Dumont, RJ, Verma, S, Okonkwo, DO, Hurlbert, RJ, Boulos, PT, Ellegala, DB & Dumont, AS 2001, 'Acute spinal cord injury, part II: Contemporary pharmacotherapy', Clinical Neuropharmacology, vol. 24, no. 5, pp. 265-279. https://doi.org/10.1097/00002826-200109000-00003
Dumont, Randall J. ; Verma, Subodh ; Okonkwo, David O. ; Hurlbert, R. John ; Boulos, Paul T. ; Ellegala, Dilantha B. ; Dumont, Aaron S. / Acute spinal cord injury, part II : Contemporary pharmacotherapy. In: Clinical Neuropharmacology. 2001 ; Vol. 24, No. 5. pp. 265-279.
@article{3114ad7d956c4adaacf1d1aeafe9d886,
title = "Acute spinal cord injury, part II: Contemporary pharmacotherapy",
abstract = "Spinal cord injury (SCI) remains a common and devastating problem of modern society. Through an understanding of underlying pathophysiologic mechanisms involved in the evolution of SCI, treatments aimed at ameliorating neural damage may be developed. The possible pharmacologic treatments for acute spinal cord injury are herein reviewed. Myriad treatment modalities, including corticosteroids, 21-amino-steroids, opioid receptor antagonists, gangliosides, thyrotropin-releasing hormone (TRH) and TRH analogs, antioxidants and free radical scavengers, calcium channel blockers, magnesium replacement therapy, sodium channel blockers, N-methyl-D-aspartate receptor antagonists, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid-kainate receptor antagonists, modulators of arachadonic acid metabolism, neurotrophic growth factors, serotonin antagonists, antibodies against inhibitors of axonal regeneration, potassium channel blockers (4-aminopyridine), paclitaxel, clenbuterol, progesterone, gabexate mesylate, activated protein C, caspase inhibitors, tacrolimus, antibodies against adhesion molecules, and other immunomodulatory therapy have been studied to date. Although most of these agents have shown promise, only one agent, methylprednisolone, has been shown to provide benefit in large clinical trials. Given these data, many individuals consider methylprednisolone to be the standard of care for the treatment of acute SCI. However, this has not been established definitively, and questions pertaining to methodology have emerged regarding the National Acute Spinal Cord Injury Study trials that provided these conclusions. Additionally, the clinical significance (in contrast to statistical significance) of recovery after methylprednisolone treatment is unclear and must be considered in light of the potential adverse effects of such treatment. This first decade of the new millennium, now touted as the Decade of the Spine, will hopefully witness the emergence of universal and efficacious pharmacologic therapy and ultimately a cure for SCI.",
keywords = "Drug therapy, NASCIS clinical trials, Pharmacotherapy, Spinal cord injury",
author = "Dumont, {Randall J.} and Subodh Verma and Okonkwo, {David O.} and Hurlbert, {R. John} and Boulos, {Paul T.} and Ellegala, {Dilantha B.} and Dumont, {Aaron S.}",
year = "2001",
month = "10",
day = "9",
doi = "10.1097/00002826-200109000-00003",
language = "English (US)",
volume = "24",
pages = "265--279",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Acute spinal cord injury, part II

T2 - Contemporary pharmacotherapy

AU - Dumont, Randall J.

AU - Verma, Subodh

AU - Okonkwo, David O.

AU - Hurlbert, R. John

AU - Boulos, Paul T.

AU - Ellegala, Dilantha B.

AU - Dumont, Aaron S.

PY - 2001/10/9

Y1 - 2001/10/9

N2 - Spinal cord injury (SCI) remains a common and devastating problem of modern society. Through an understanding of underlying pathophysiologic mechanisms involved in the evolution of SCI, treatments aimed at ameliorating neural damage may be developed. The possible pharmacologic treatments for acute spinal cord injury are herein reviewed. Myriad treatment modalities, including corticosteroids, 21-amino-steroids, opioid receptor antagonists, gangliosides, thyrotropin-releasing hormone (TRH) and TRH analogs, antioxidants and free radical scavengers, calcium channel blockers, magnesium replacement therapy, sodium channel blockers, N-methyl-D-aspartate receptor antagonists, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid-kainate receptor antagonists, modulators of arachadonic acid metabolism, neurotrophic growth factors, serotonin antagonists, antibodies against inhibitors of axonal regeneration, potassium channel blockers (4-aminopyridine), paclitaxel, clenbuterol, progesterone, gabexate mesylate, activated protein C, caspase inhibitors, tacrolimus, antibodies against adhesion molecules, and other immunomodulatory therapy have been studied to date. Although most of these agents have shown promise, only one agent, methylprednisolone, has been shown to provide benefit in large clinical trials. Given these data, many individuals consider methylprednisolone to be the standard of care for the treatment of acute SCI. However, this has not been established definitively, and questions pertaining to methodology have emerged regarding the National Acute Spinal Cord Injury Study trials that provided these conclusions. Additionally, the clinical significance (in contrast to statistical significance) of recovery after methylprednisolone treatment is unclear and must be considered in light of the potential adverse effects of such treatment. This first decade of the new millennium, now touted as the Decade of the Spine, will hopefully witness the emergence of universal and efficacious pharmacologic therapy and ultimately a cure for SCI.

AB - Spinal cord injury (SCI) remains a common and devastating problem of modern society. Through an understanding of underlying pathophysiologic mechanisms involved in the evolution of SCI, treatments aimed at ameliorating neural damage may be developed. The possible pharmacologic treatments for acute spinal cord injury are herein reviewed. Myriad treatment modalities, including corticosteroids, 21-amino-steroids, opioid receptor antagonists, gangliosides, thyrotropin-releasing hormone (TRH) and TRH analogs, antioxidants and free radical scavengers, calcium channel blockers, magnesium replacement therapy, sodium channel blockers, N-methyl-D-aspartate receptor antagonists, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid-kainate receptor antagonists, modulators of arachadonic acid metabolism, neurotrophic growth factors, serotonin antagonists, antibodies against inhibitors of axonal regeneration, potassium channel blockers (4-aminopyridine), paclitaxel, clenbuterol, progesterone, gabexate mesylate, activated protein C, caspase inhibitors, tacrolimus, antibodies against adhesion molecules, and other immunomodulatory therapy have been studied to date. Although most of these agents have shown promise, only one agent, methylprednisolone, has been shown to provide benefit in large clinical trials. Given these data, many individuals consider methylprednisolone to be the standard of care for the treatment of acute SCI. However, this has not been established definitively, and questions pertaining to methodology have emerged regarding the National Acute Spinal Cord Injury Study trials that provided these conclusions. Additionally, the clinical significance (in contrast to statistical significance) of recovery after methylprednisolone treatment is unclear and must be considered in light of the potential adverse effects of such treatment. This first decade of the new millennium, now touted as the Decade of the Spine, will hopefully witness the emergence of universal and efficacious pharmacologic therapy and ultimately a cure for SCI.

KW - Drug therapy

KW - NASCIS clinical trials

KW - Pharmacotherapy

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=0034812468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034812468&partnerID=8YFLogxK

U2 - 10.1097/00002826-200109000-00003

DO - 10.1097/00002826-200109000-00003

M3 - Article

C2 - 11586111

AN - SCOPUS:0034812468

VL - 24

SP - 265

EP - 279

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 5

ER -